Document:

Exhibit
10.1

    

     

    University
of Louisville Research Foundation

    Amendment
No. 1 to

    Sponsored
Research Agreement

    

    

    THIS
Amendment No. 1 (“Amendment”) is made and effective as of the last date of
signature below (“Effective Date”), by and between the University of Louisville
Research Foundation, Inc. (hereinafter “ULRF”) a Kentucky non-profit corporation
having an office at MedCenter One, 501 E. Broadway, Suite 200, Louisville, KY
40202-1798 as the agent of the University of Louisville (hereinafter "UofL") for
receiving grants and research agreements from external funding sources and which
owns and controls intellectual property on behalf of UofL (collectively
“Institution”) and NeoStem, Inc. with a principal place of business at 420
Lexington Avenue, Suite 450, New York, NY  10170 (hereinafter
“SPONSOR”).

    

    WHEREAS,
ULRF and SPONSOR entered into that certain Sponsored Research Agreement as of
November 13, 2007 (the “Original Agreement”); and

    

    WHEREAS,
ULRF and SPONSOR wish to amend the Original Agreement to amend the research
program set forth therein to provide for certain additional research in return
for receiving certain rights in the research results and to provide for support
related to such additional research.

    

    NOW,
THEREFORE, the parties hereto agree as follows:

    

    
      	
              1.

            	
              DEFINITIONS

            

    

    

    Unless
otherwise set forth herein, initially capitalized terms not otherwise defined
herein shall have the meaning ascribed to them in the Original
Agreement.

    

    
      	
              2.

            	
              RESEARCH

            

    

    

    The
Research Plan is hereby amended to provide that the research set forth in
Appendix A-1 hereto (“Pre-Aim 1”) shall become part of the Original Agreement
and Pre-Aim 1 shall be conducted prior to the conduct of the Research set forth
in the Original Agreement.  SPONSOR will use its best reasonable
efforts to provide to Principal Investigator no later than October 17, 2008 the
de-identified samples required for Institution’s performance of its portion on
Pre-Aim 1.  Institution will use its best reasonable efforts to
complete its portion of Pre-Aim 1 within a period of two (2) months from the
date of receipt of such necessary samples from SPONSOR.

    

    Sponsor
has been advised by Institution that the Pre-Aim 1 protocol titled “Isolation of
Very Small Embryonic like Stem Cells (VSELS) from Peripheral Blood after G-CSF
mobilization”, IRB tracking # 08.0255, was determined by the University of
Louisville Institutional Review Board (IRB) to be an Exempt study as defined by
the IRB and unless said protocol is modified, no further continuing review
and/or approvals are required for the research study under Pre-Aim
1.  Institution acknowledges that, upon receipt of the apheresis
product referred to in Pre-Aim 1, Pre-Aim 1 shall commence
promptly.

    

    
      	
              4. 

            	
              PAYMENT
      OF COSTS

            

    

    

    4.1       In
consideration of ULRF’s performance hereunder and under the Original Agreement,
SPONSOR agrees to support costs incurred in performance of the Research in the
aggregate amount of Three Hundred Ninety-Nine Thousand Five Hundred Twelve U.S.
Dollars (US$399,512), inclusive of applicable Facilities & Administrative
Costs calculated at Institution’s rate in effect as of the Effective Date of the
Original Agreement on the terms set forth herein and therein. It is
acknowledged that of this amount, $375,000 relates to the Research under the
Original Agreement and $24,512 relates to Pre-Aim 1.  As of the date
of this Amendment, no amounts are payable under the Original Agreement;
provided, however, that on April 3, 2008, SPONSOR prepaid $50,000 under the
Original Agreement.  ULRF and

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    SPONSOR
agree that the this $50,000 prepayment shall be credited to the $24,512 payable
for the conduct of Pre-Aim 1 of the Additional Research on the date that Pre-Aim
1 commences.

    

    NO OTHER CHANGES

    

    Except as
set forth in this Amendment, the terms of the Original Agreement shall remain
unchanged and the rights and obligations of the parties under the Original
Agreement shall apply equally to the conduct of Pre-Aim 1 provided for
hereby.

    

    

    [remainder
of page left blank intentionally]

     

     

     

     

     

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    IN WITNESS WHEREOF, the
parties hereto have executed this Agreement as of the date first above
written.

    

    

    
      
        
          
            
              
                
                  
                    
                      
                        
                          
                            
                              
                                
                                  	
                                          THE
      UNIVERSITY OF LOUISVILLE

                                        	 	
                                          NEOSTEM,
      INC.

                                        
	
                                          RESEARCH
      FOUNDATION, INC.

                                        	 	 
      	 
      
	 
      	 
      	 	 
      	 
      
	
                                          Signature:

                                        	
                                          /s/
      David D. King

                                        	 	
                                          Signature:

                                        	
                                          /s/
      Robin Smith

                                        
	 
      	 
      	 	 
      	 
      
	
                                          Printed
      Name:

                                        	
                                          David
      D. King

                                        	 	
                                          Printed
      Name:

                                        	
                                          Robin
      Smith

                                        
	 
      	 
      	 	 
      	 
      
	
                                          Title:

                                        	
                                          Director,
      Office of Industry Contracts

                                        	 	
                                          Title:

                                        	
                                          CEO

                                        
	 
      	 
      	 	 
      	 
      
	
                                          Date:

                                        	
                                          10/7/2008

                                        	 	
                                          Date:

                                        	
                                          10/3/08

                                        

                                

                              

                            

                          

                        

                      

                    

                  

                

              

            

          

        

      

    

    

    

    Principal
Investigator, while not a party to this Agreement, by his/her signature
acknowledges that he/she: (1) has read and agrees to abide by the terms and
conditions that apply to the Principal Investigator,  (2) agrees to
conduct/perform the research as outlined in the Research Statement of Work, and
(3) if applicable, will see that the work within the scope of this agreement is
performed in accordance with an approved University/Institution management
plan.1

    

    
      
        
          
            
              
                	
                        Name:

                      	
                        Mariusz
      Z. Ratajczak, M.D., Ph.D.

                      	 
	 
      	 
      	 
	
                        Signature:

                      	
                        /s/
      Mariusz Z. Ratajczak

                      	 
	 
      	 
      	 
	
                        Title:

                      	
                        Professor,
      Medical Oncology

                      	 
	 
      	 
      	 
	
                        Date:

                      	
                        10/7/08

                      	 

              

            

          

        

      

    

    

    

    

    

    

    

    

    

    

      

    

    
      1  “Management
Plan" means a written plan for the management, reduction or elimination
of a potential financial conflict of interest relating to research. It relies
upon, and is therefore limited by, good faith disclosures about significant
financial interests made, and other information provided by, a covered
individual to the University.Exhibit
10.2

    

    

    AMENDMENT
NO. 1 TO

     

    EXCLUSIVE
LICENSE AGREEMENT

     

    BETWEEN

     

    UNIVERSITY
OF LOUISVILLE RESEARCH FOUNDATION, INC.

     

    AND

     

    STEM
CELL TECHNOLOGIES, INC.

     

    This
Amendment No. 1 (the “Amendment”) is entered into this 27th day of February 2009
to that exclusive license agreement (the "Original Agreement") entered into the
12th day of November 2007 by and between the University of Louisville Research
Foundation, Inc.  ("ULRF"), a Kentucky 501 (c) 3 non-profit
corporation having an office at Med Center Three, 201 E. Jefferson Street, Suite
215, Louisville, KY 40202 as the agent of the University of Louisville ( “UofL”)
and Stem Cell Technologies, Inc. (“LICENSEE”), a Florida corporation and
wholly-owned subsidiary of NeoStem, Inc., a Delaware corporation, each with its
principal place of business located at 420 Lexington Avenue, Suite 450, New
York, New York  10021.

     

    RECITALS

     

    
      	
               
      

            	
              WHEREAS,
      ULRF and Licensee entered into the Original Agreement whereby Licensee
      licensed the rights to the Licensed Technology for the commercial
      development, use and sale of the Licensed
  Technology.

            

    

     

    
      	
               
      

            	
              WHEREAS,
      ULRF and Licensee after discussion desire to amend certain terms of the
      Original Agreement as hereinafter
described;

            

    

     

    
      	
               
      

            	
              WHEREAS,
      in consideration of the mutual promises contained herein and other good
      and valuable consideration, the receipt and sufficiency of which is hereby
      acknowledged.

            

    

     

     

    NOW, THEREFORE, ULRF and
LICENSEE hereby agree as follows:

     

     

    
      	
            	
              1. 

            	
               Section
      5.1 of the Original Agreement is hereby amended to read in its entirety as
      follows:

            

    

     

    “5.1  License
Issue Fee.  LICENSEE shall pay to ULRF a non-creditable,
non-refundable License Issue Fee of  forty six thousand dollars
($46,000).  Said License Issue Fee shall be payable no later than five
(5) business days after the full execution of this Amendment.”

     

    
      	
            	
              2. 

            	
               Section
      6.1.2.2 of the Original Agreement is hereby amended to read in its
      entirety as follows:

            

    

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    “6.1.2 .2 Prepayment of Future Patent
Office Expenses.  No later than five (5) business days after
the full execution of this Amendment, Licensee shall pay a non-refundable twenty
thousand dollars ($20,000), which shall be creditable against the first twenty
thousand ($20,000) of patent expenses incurred after the Effective Date of this
Agreement.”

     

    
      	
            	
              3. 

            	
               “Section
      3.3 – Development Plan” shall be amended to read in its entirety as
      follows:

            

    

     

    3.3          Development
Plan.  Upon execution of this Agreement, LICENSEE shall submit
an initial Development Plan outlining work to be completed during the first two
and one-half (2.5) years of the Research Period (as defined in the Sponsored
Research Agreement described in Section 3.6 herein), which shall also serve as
the research plan of the Sponsored Research Agreement.  No later than
December 31, 2010, LICENSEE shall provide ULRF with a list of its desired,
specific fields of use of the Licensed Technology and the definition of Field of
Use set forth in 1.1.3 shall be deemed amended accordingly. No later than June
30, 2011, LICENSEE will provide ULRF with a draft Development Plan written in
the format set forth in Exhibit D for each specific field of use of the Licensed
Technology included on the aforementioned list, satisfactory to ULRF, in its
reasonable discretion and describing the steps it intends to take which it
believes in good faith will result in allowing the inventions of the Licensed
Patents to be utilized to provide Licensed Products for sale in the commercial
market, which shall further include those steps taken, or to be taken, by
Affiliates and sublicensees, as it may have been advised by Affiliates and
sublicensees.  For each specified field of use included on the
aforementioned list for which ULRF does not receive a timely Development Plan
from LICENSEE satisfactory to ULRF in its reasonable discretion, ULRF may
withdraw that field of use from this Agreement the definition of Field of Use in
1.1.3 shall again be deemed amended to reflect the narrowed fields of use and
ULRF may license such use to a third party, subject to prior notice to Licensee
and an opportunity to cure as set forth in Section
12.1.1.1.   For each new field of use desired by LICENSEE but not
included on the list submitted to ULRF by LICENSEE, LICENSEE may request the
addition of the new field(s) of use and its corresponding Development Plan to
this Agreement in accordance with Section 13.3 of this Agreement.

     

    Except as set forth herein, the
Original Agreement shall remain unchanged.  Initially capitalized
terms not otherwise described herein shall have the meaning set forth in the
Original Agreement.

     

    THEREFORE,
the parties have executed this Agreement in duplicate originals by their duly
authorized officers or representatives.

     

    
      
        	
                UNIVERSITY
      OF LOUISVILLE

                RESEARCH
      FOUNDATION, INC.

                 

                /s/ James R.
      Zanewicz                                                                

                James
      R. Zanewicz, Director

                 

                Date
      3/4/09                                                                

                 

              	
                Stem
      Cell Technologies Inc.

                 

                 

                /s/ Robin
      Smith                                                                

                Robin Smith, President

                 

                Date           2/28/2009

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}]]